Foodlaw-Reading
Dr David Jukes, The University of Reading, UK
|
|
DoH Interested Parties Update, 2 June 2014
A copy of the Update is available on this website. See: Update from the European Commission’s Working Group 16 May 2014 The following is listing of the items mentioned:
1. Discussion on a draft Commission Regulation on the authorisation of health claim related to glycaemic carbohydrates and recovery of normal muscle function(contraction) after strenuous exercise (Q-2013-00234):
2. Discussion on a health claim related to hydroxyanthracene derivatives (HD) and improvement of bowel function (Q-2013-00650)
3. Discussion on health claims related to “non-fermentable carbohydrates” and maintenance of tooth mineralisation (Q-2013-00040) and for a health claim related to “non-digestible” carbohydrates and reduction of post–prandial glycaemic responses (Q-2013-0015)
4. Discussion on five health claims related to glucose and energy-yielding metabolism (Q-2012-00266, Q-2012-00267, Q-2012-00268, Q-2012-00269 and Q-2012-00270)
5. Discussion on a draft Commission Regulation refusing to authorise health claims for Yestimum® , Transitech®, Bimuno GOS®, Lactobacillus rhamnosus GG (LGG), VeriSol® P and zinc (Q-2012-00761, Q-2013-00087, Q-2012-01007, Q2013-00015, Q-2012-00839, Q-2010-01092) & Discussion on Working Document (SANCO/11586/2013) Statement concerning target populations under medical treatment SCFCAH meeting -13 June 2014
6. Discussion of a draft Commission Regulation refusing to authorise health claims on Caffeine (Q-2013-00399), Rosbacher drive ® (Q-2013-00444), and Cytidine 5-diphosphocholone (CDP-choline or citicoline) (Q-2013-00757)
7. New Article 14(1)(a) claims-h Discussion on a draft Commission Regulation refusing to authorise health claims on “Beta-palmitate” (Q-2008-174), “Choline” (Q-2008-134), “Complex carbohydrates” (Q-2008-131) Choline is needed for the development of brain of infants and young children from birth to three years” (Q-2008-134)
8. Information on the procedures to be followed in view of the expiry date (18/12/2014) of the restriction of use of the claim on Water-Soluble Tomato Concentrate (WSTC) I and II and normal platelet aggregation (EFSA opinions Q-2009-00229, Q-2010-00809)
Next Working Group Meeting: Provisionally September 2014
